Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Prospective, Comparative, Active-controlled, Randomized, Open-label, Multicenter Study to Compare the Safety and Efficacy of Teriparatide of Enzene Biosciences Ltd. versus Forteo of Eli Lilly in the Treatment of Postmenopausal Osteoporosis

Trial Profile

A Prospective, Comparative, Active-controlled, Randomized, Open-label, Multicenter Study to Compare the Safety and Efficacy of Teriparatide of Enzene Biosciences Ltd. versus Forteo of Eli Lilly in the Treatment of Postmenopausal Osteoporosis

Recruiting
Phase of Trial: Phase III

Latest Information Update: 24 Nov 2018

At a glance

  • Drugs Teriparatide (Primary)
  • Indications Postmenopausal osteoporosis
  • Focus Registrational; Therapeutic Use
  • Sponsors Alkem Laboratories; Enzene Biosciences
  • Most Recent Events

    • 12 Nov 2018 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top